Published in Oncotarget on April 04, 2017
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol (2011) 3.80
Ovarian cancer. Lancet (2014) 3.80
Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol (2004) 3.64
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature (2016) 2.11
Senescence, apoptosis and therapy--cutting the lifelines of cancer. Nat Rev Cancer (2003) 1.91
ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett (2000) 1.81
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer (2012) 1.70
The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst (2015) 1.70
A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood (1995) 1.48
Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene (2011) 1.44
Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab (2004) 1.35
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer (2012) 1.30
Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res (2008) 1.27
Identification of genes expressed in malignant cells that promote invasion. Cancer Res (2003) 1.20
Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood (2004) 1.17
Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer (2006) 1.16
Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Cell Oncol (2006) 1.13
Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer (2001) 1.12
Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. Elife (2014) 1.06
Identification of the functional role of AF1Q in the progression of breast cancer. Breast Cancer Res Treat (2007) 1.00
Characterization of the recurrent translocation t(1;1)(p36.3;q21.1-2) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis. Genes Chromosomes Cancer (2003) 1.00
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics. Am J Hematol (2009) 0.98
Carbonyl reductase: a novel metastasis-modulating function. Cancer Res (2000) 0.97
Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids (2013) 0.97
Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol (2012) 0.96
Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol (Lausanne) (2014) 0.94
Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. Cancer Lett (2011) 0.94
MLL-AF1q fusion resulting from t(1;11) in acute leukemia. Leukemia (1999) 0.92
Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One (2014) 0.92
Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway. Mol Cancer Ther (2008) 0.92
Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancer. Oncotarget (2015) 0.90
Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ (2004) 0.89
Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene. Int J Cancer (2012) 0.89
S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene (2013) 0.89
Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings. Leukemia (2003) 0.89
Ovarian cancer: involvement of the matrix metalloproteinases. Reproduction (2015) 0.88
Increased AF1q gene expression in high-risk myelodysplastic syndrome. Br J Haematol (2005) 0.87
MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis. Oncotarget (2016) 0.85
The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adh Migr (2013) 0.84
AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget (2015) 0.83
AF1q: a novel mediator of basal and 4-HPR-induced apoptosis in ovarian cancer cells. PLoS One (2012) 0.81
AF1q enhancement of gamma irradiation-induced apoptosis by up-regulation of BAD expression via NF-kappaB in human squamous carcinoma A431 cells. Oncol Rep (2010) 0.80
MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling. Oncotarget (2016) 0.78
Molecular regulation of ovarian cancer cell invasion. Tumour Biol (2014) 0.77
Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing epithelial-mesenchymal transition in human ovarian cancer. Am J Cancer Res (2016) 0.76